Abstract: The present invention relates to a composition for preventing or treating menopausal syndrome, containing a medicinal herb extract as an active ingredient. The composition has effects of alleviating heart function deterioration and depression, which are caused by menopause, and has biostability, thereby being usable as a composition for preventing or treating female menopausal syndrome.

Abstract: The present invention relates to a pharmaceutical composition for prevention or treatment of prostatic hyperplasia among Aging Males' Symptoms, comprising a Lespedeza cuneata extract and a Trigonellae semen extract, and a preparation method thereof characterized in that the complex composition produced by mixing the Lespedeza cuneata extract and the Trigonellae semen extract has a mixing ratio by weight of 1˜10:1˜9 of the Lespedeza cuneata extract and the Trigonellae semen extract, preferably, a mixing ratio by weight of 1:1˜4. The pharmaceutical preparation according to the present invention comprising the Lespedeza cuneata extract or complex composition of the Lespedeza cuneata extract and the Trigonellae semen extract have an effect on improvement of erectile function and for prevention or treatment of prostatic hyperplasia at the same time, among Aging Males' Symptoms, without any side effect.

Abstract: The invention relates to a soybean seed extract, method for producing the same and uses of the extract of soybean seeds in promoting wound healing, promoting neuron cell proliferation and/or treating brain diseases and/or neurodegenerative diseases, treating breast cancer, reducing side effects of interfering with DNA and/or RNA replication drugs and/or enhancing pharmaceutical effects of interfering with DNA and/or RNA replication drugs.

Abstract: Methods of treating symptoms of type 2 diabetes in a human subject by administering a composition comprising urolithin A and urolithin B, are provided. Methods of treating symptoms of type 2 diabetes and metabolic syndrome in a human subject by administering a composition comprising neem extract are provided.

Abstract: The present disclosure provides an extract of Citrus reticulata unripe fruit, and a method for reducing lipid accumulation by using the extract of Citrus reticulata unripe fruit. The extract of Citrus reticulata unripe fruit includes tetramethylisoscutellarein.

Abstract: Flavonoid compositions containing the flavonoid quercetin and/or derivatives of quercetin are disclosed. The flavonoid compositions are formulated to improve the bioavailability of quercetin. Also provided herein are methods for improving athletic performance, improving cardiovascular health, and aiding in immune response and methods of improving athletic performance, improving bone health, preventing fatigue, reducing recovery time after exercise, countering oxidative stress, and/or boosting energy.

Abstract: Provided herein is a method for improving the health of an intestinal epithelial barrier using Aloe vera. The method may include administering Aloe vera extracts to intestinal epithelial cells. The decolorized aloe extract may be whole leaf extract, whole leaf dry extract, inner leaf dry extract, digested whole leaf extract, digested whole leaf dry extract, digested inner leaf dry extract, or a combination thereof.

Abstract: An engineered nanoparticle having a curcumin carbon quantum dot and the use thereof for antiviral application are disclosed. A method of preparation of a curcumin carbon nanoparticle is also disclosed, the method comprises heating a curcumin powder at a temperature range from 120 to 210° C. to yield a residue; dissolving the residue with sodium phosphate buffer in a solution; and purifying the solution.

Abstract: This invention relates to methods for administering an effective amount of a dietary or nutritional supplement composition that effectively changes the levels of biomarkers in the synovium of a joint and resulting in decreased pain and ultimately better outcomes for subjects. The formulation comprises an effective amount of the following: Boswellia; Vitamin C; Ginger; Turmeric; Vitamin D3; and Rutin. In a preferred embodiment of the composition of the invention, the composition is substantially free of omega-3 fatty acids.

Abstract: The present invention includes methods of inhibiting or suppressing cellular secretory processes. More specifically the present invention relates to inhibiting or reducing the release of inflammatory mediators from inflammatory cells by inhibiting the mechanism associated with the release of inflammatory mediators from granules in inflammatory cells. In this regard, the present invention discloses an intracellular signaling mechanism that illustrates several novel intracellular targets for pharmacological intervention in disorders involving secretion of inflammatory mediators from vesicles in inflammatory cells. Peptide fragments and variants thereof of MANS peptide as disclosed in the present invention are useful in such methods.

Abstract: The invention relates to a topical composition containing a variant of an OB-fold protein, and also to the process for preparing the same.

Abstract: Antimicrobial peptides, compositions and methods are described that are useful for treating infectious disease, including those caused by drug resistant Gram-negative bacteria (e.g., Pseudomonas and Acinetobacter) and parasite-caused disease such as malaria. The peptides include a modular kinocidin gamma-core connected directly, or through a short spacer, to a kinocidin C-terminal alpha-helix.

Abstract: The present invention relates to novel antimicrobial peptide and variants thereof. The invention further relates to method of killing or inhibiting growth of microbes and use of the peptide here disclosed as a medicament, feed additive, preservative or surfactant.

Abstract: The present invention concerns clusterin for use in the treatment of thrombotic microangiopathies, and a pharmaceutical composition comprising clusterin for use in the treatment of thrombotic microangiopathies, said composition not comprising von Willebrand factor protease. The present invention also concerns an ex vivo method for stratifying a patient suffering, or likely to be suffering, from TMA, comprising the following steps: 1) measuring, in a biological sample from said patient, the amount LC of clusterin, and 2) comparing the amount Lc measured in step 1) with an amount Lref of clusterin by calculating the score S1=LC/Lref, in which: •If S1?1, the patient is considered to be likely to benefit from a treatment of the TMA with clusterin, •If S1>1, the patient is not considered to be likely to benefit from treatment of TMA with clusterin.

Abstract: The present invention relates to a SOCS1-derived peptide for use in chronic complications of diabetes, particularly ocular, renal, nerve and vascular complications, as well as compositions containing same and isolated polynucleotides encoding same. The present invention also relates to the SOCS1-derived peptide for topical use in the treatment and/or prevention of neurodegenerative diseases of the retina, particularly in the early stages of diabetic retinopathy and other diseases of the retina in which neurodegeneration plays an essential role.

Abstract: This invention provides for a network of cell-derived microfilaments. Also provided are methods of producing a network of microfilaments via culturing cells in a matrix support and cell culture medium wherein the cells proliferate and form aggregated cell masses, which produce microfilaments external to and surrounding the cell masses, and wherein the extracellular microfilaments connect and form a continuous extracellular microfilament network, and methods for treating a medical condition as well as facilitating wound repair and tissue regeneration comprising applying the microfilament network to an area in need of treatment.

Abstract: The present invention includes compositions and methods for treating diseases or disorders associated with pathological calcification or pathological ossification. In certain embodiments, the diseases or disorders are selected from the group consisting of Generalized Arterial Calcification of Infancy (GACI), Idiopathic Infantile Arterial Calcification (IIAC), Ossification of the Posterior Longitudinal Ligament (OPLL), hypophosphatemic rickets, osteoarthritis, calcification of atherosclerotic plaques, PXE, hereditary and non-hereditary forms of osteoarthritis, ankylosing spondylitis, hardening of the arteries occurring with aging, calciphylaxis resulting from end stage renal disease and progeria.

Abstract: Provided is a method of treating a bladder cancer in an animal or human comprising: administering to an animal or human patient a therapeutic composition comprising a first fusion protein capable of specifically binding to an epidermal growth factor receptor (EGFR) on the surface of a cancer cell and comprising an epidermal growth factor (EGF) polypeptide conjugated to a bacterial toxin polypeptide and a second fusion protein comprising an anthrax Lethal Factor N-terminus (LFN) conjugated to a Diptheria Toxin A (DTA) catalytic domain.

Abstract: Present invention relates to a composition for use in the treatment of an individual suffering from a condition necessitating new bone formation. The present invention further relates to osteoconductive carriers that have been provided with the composition of present invention for use in the treatment of an individual suffering a condition necessitating new bone formation. Also, present invention relates to a method for bone tissue generation in an individual suffering a condition necessitating new bone formation, such as large bone defects, segmental bone defects, structural bone defects, bone fractures, non-unions of bone fractures, fusion of joints including spinal fusions.

Abstract: The application provides new compositions and methods for stimulating the production of natural killer (NK) cells in a subject. NK cells can be selectively expanded with a combination of stimulating ligands. Methods and compositions for the administration of stimulatory ligands modified to self-insert into tumor cells, thereby stimulating an increase in the number of NK cells in proximity to a tumor, are also described.

Abstract: The present invention relates to the use of liver-selective glucokinase activators and a GLP1 analog in restoring insulin sensitivity and treating type II diabetes, including reducing body weight in subjects undergoing type II diabetes treatment.

Abstract: Intestinal absorption is enhanced in short bowel syndrome patients presenting with colon-in-continuity by treatment with a GLP-2 receptor agonist, such as teduglutide.

Abstract: The present invention provides rapid-acting insulin and insulin analogue formulations. The invention further provides delivery devices, particularly infusion sets, which allow for the rapid absorption of insulin and insulin analogues, as well as other active agents. Methods of using the insulin and insulin analogue formulations as well as the insulin delivery devices for treating subjects with diabetes mellitus are also provided.

Abstract: Methods related to the treatment of diabetes and improving the control of blood glucose levels are provided. In particular, methods are provided for effectively reducing postprandial glucose excursions while reducing the incidence of clinically significant late postprandial hypoglycemia by administered an insulin composition in a form suitable for pulmonary administration. Additionally, methods for effectively reducing post-prandial glucose excursions while reducing the incidence of clinically significant late postprandial hypoglycemia by administered an insulin composition in a form suitable for pulmonary administration along with a long-acting basal insulin.

Abstract: A pharmaceutical composition for oral administration is disclosed herein, comprising a therapeutically active agent, SNAC and at least one antacid compound. Further disclosed herein is a pharmaceutical composition unit dosage form for oral administration of a therapeutically active agent is provided herein, the unit dosage form comprising: a core comprising the therapeutically active agent and SNAC (sodium 8-N-(2-hydroxybenzoyl)aminocaprylate); and an external layer comprising at least one protective agent selected from the group consisting of an antacid compound and a protease inhibitor. Methods and uses utilizing the aforementioned pharmaceutical compositions, as well as methods and uses utilizing co-administration, by oral administration, of at least one antacid composition, and a composition comprising the therapeutically active agent and SNAC, are further disclosed herein, for use in treating a condition treatable by oral administration of the therapeutically active agent.

Abstract: The present invention refers to nanoparticles comprising a core, said core comprising a non-crosslinked albumin matrix and a monoclonal antibody, optionally coated with a non-ionic polymer for use as a medicament, to a pharmaceutical composition comprising said nanoparticles, as well as their use in the treatment of cancer an ocular diseases.

Abstract: Provided are an upstream Open Reading Frame (uORF) of a Phosphatase and Tensin homolog (PTEN) gene and a protein coded by the uORF. A potential ORF of 138 bases (45aa-uORF) in the 5?UTR of the PTEN, coding an oligopeptide of 45 amino acids (named PTEN-45aa) plays an important role in the development and progression progress of tumors. Further provided are a new diagnostic and therapeutic method and a drug screening platform for PTEN expression regulation related diseases, in particular neuroglioma. Also provided is a polypeptide for treatment of PTEN expression regulation related diseases.

Abstract: This disclosure relates to recombinant FXa polypeptides that can be used as antidotes to completely or partially reverse an anti-coagulant effect of a coagulation inhibitor in a subject, preferably a direct factor Xa inhibitor. Disclosed herein are recombinant factor Xa proteins and a method of completely or partially reversing an anti-coagulant effect of a coagulation inhibitor in a subject.

Abstract: This disclosure relates to recombinant FXa polypeptides that can be used as antidotes to completely or partially reverse an anti-coagulant effect of a coagulation inhibitor in a subject, preferably a direct factor Xa inhibitor. Disclosed herein are recombinant factor Xa proteins and a method of completely or partially reversing an anti-coagulant effect of a coagulation inhibitor in a subject.

Abstract: A method for treating an abnormality of the first metatarsophalangeal joint of the foot of a mammal includes electrically stimulating a site on each of the extensor hallucis brevis and adductor hallucis muscles of a foot of the mammal affected by the abnormality, and visually confirming that the stimulated muscles responds to the stimulation by contracting. An amount of botulinum toxin effective to treat the abnormality is then injected to the confirmed sites on the extensor hallucis brevis and the adductor hallucis muscles of the affected foot.

Abstract: An easily administrable drug treatment to increase the recanalization rate associated with intravenously t-PA would represent a major advance in the acute ischemic stroke (AIS) management. The inventors demonstrate the presence of NETs network in intracranial thrombus extracted during AIS reperfusion procedures. Thrombi are encapsulated by these NETs network, which confer t-PA resistance. In fact, in presence of DNAse 1, t-PA-induced thrombolysisis accelerated, whereas DNAse alone is inefficient. These results suggest that a co-therapy associating t-PA and DNAse 1 may potentialize t-PA efficacy. Accordingly, the present invention relates to a method of treating an acute ischemic stroke (AIS) in a patient in need thereof comprising administering to the patient a therapeutically effective combination of t-PA and DNAse, wherein administration of the combination results in enhanced therapeutic efficacy relative to the administration of t-PA alone.

Abstract: Provided herein, among other things, is a method for prevention and/or treatment of an autoimmune disease. In some embodiments, the method may comprise administering to a subject a composition, said composition comprising at least one ? cell autoantigen, by intralymphatic injection or injection directly into a lymph node.

Abstract: This invention relates to methods and compositions for preventing and treating certain diseases or disorders characterized by synaptic dysfunction and neurodegeneration, including Alzheimer's disease by increasing the levels of a certain protein ubiquitin ligase Ube3A.

Abstract: The invention relates to humanized antibodies that bind to an epitope at the N-terminus of pyroglutamated amyloid beta (A? N3pE) peptide and to preventive and therapeutic treatment of diseases and conditions that are related to accumulation and deposition of amyloid peptides, such as amyloidosis, a group of disorders and abnormalities associated with pyroglutamated amyloid peptide, like Alzheimer's disease, Down's syndrome, cerebral amyloid angiopathy and other related aspects. More specifically, it pertains to the use of humanized monoclonal antibodies to bind pyroglutamated amyloid beta peptide in plasma, brain, and cerebrospinal fluid to prevent accumulation or to reverse deposition of A? N3pE within the brain and in various tissues in the periphery, and to alleviate amyloidosis. The present invention further pertains to diagnostic assays for the diagnosis of amyloidosis using the humanized antibodies of the invention.

Abstract: The present invention generally relates to a personalized cancer vaccine comprising a recombinant poxvirus encoding one or more neopeptide(s) or a composition comprising such a recombinant poxvirus and a pharmaceutically acceptable vehicle as well as the use of said personalized cancer vaccine for treating a cancerous subject in need thereof. A specific embodiment is directed to a method of providing such a vaccine or composition comprising an identification step comprising a) extracting the DNA from a tumor sample and a non-tumor sample, b) selecting target regions, preferably the entire coding regions of the genome (exome), c) sequencing said target regions (e.g. the exome) from said extracted DNAs and d) identifying one or more tumor-specific mutation(s) by comparing the DNA sequences obtained from said tumor and non-tumor samples. Embodiments also include a method of treating cancer or preventing its relapse comprising administration of such a personalized cancer vaccine.

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

Abstract: Androgen receptor-based vaccines for eliciting an immune reaction in vivo against cells expressing androgen receptor are disclosed. The vaccines are useful in the treatment of prostate cancer. Also disclosed are methods for inducing immune reaction to androgen receptor or treating prostate cancer in a mammal, using the vaccines and pharmaceutical compositions comprising the vaccines.

Abstract: This application provides an immunity-inducing agent comprising, as an active ingredient, at least one polypeptide having immunity-inducing activity and selected from (a) polypeptides consisting of amino acid sequences represented by SEQ ID NO: 8, 4, 6, 10, 12, 2 and 14, and polypeptides consisting of 7 or more consecutive amino acids in the amino acid sequences, (b) polypeptides having a sequence identity of 85% or more with the amino acid sequences represented by SEQ ID NO: 8, 4, 6, 10, 12, 2 and 14, and polypeptides consisting of 7 or more consecutive amino acids in the amino acid sequences, and (c) polypeptides comprising the polypeptides according to (a) or (b) as the partial sequences, or a recombinant vector comprising a polynucleotide encoding the polypeptide and capable of expressing the polypeptide in vivo.

Abstract: The present invention relates to stable compositions comprising acellular pertussis antigens that have not been cross-linked with a cross-linking agent such as formaldehyde or glutaraldehyde and their use as acellular pertussis components in combination vaccines. Processes for preparing these antigens and compositions are also disclosed.

Abstract: The embodiment of the invention is to enable universal non-classical MHC I peptide vaccines restricted to HLA-E, HLA-F and HLA-G. An algorithm was develop to predict HLA-E binding immunogenic or suppressorgenic peptides of the autologous origins, e.g., autoantigens, inflammatory antigens, IgE and cancer antigens, and of the microbial origins. Thus, the embodiment of the invention is to load the antigenic peptides of medical and therapeutic importance onto the non-polymorphic HLA-E, HLA-F, and HLA-G culminating in universal vaccines, bypassing highly polymorphic classical MHC I, e.g., HLA-A, HLA-B and HLA-C pathways, in order to treat autoimmune diseases, allergy, inflammatory diseases, cancers, and infectious diseases for all human population. Derlin-1 and UL40 pathways are utilized to enable antigen presentation and vaccine efficacies in the non-classical MHC I pathways.

Abstract: The present invention relates to a peptide composition capable of binding with major histocompatibility complex class I molecules to induce an anti-cancer immune response in a subject. Particularly, the peptide composition comprises at least a Four-jointed Box 1 peptide and a Melanoma Antigen family D4b peptide. The present invention further relates to the use of a peptide composition and a peptide vaccine for inducing the anti-cancer immune response in the subject.

Abstract: Protection of fish from bacterial disease by vaccination with a live attenuated strain of the causative bacterium is enhanced when the attenuated strain has been grown in an iron-limited medium.

Abstract: The present invention generally provides methods and compositions for eliciting an immune response against Neisseria spp. bacteria in a subject, particularly against a Neisseria meningitidis serogroup B strain.

Abstract: Multivalent meningococcal conjugate vaccines are administered according to a schedule in which a first dose is administered to a patient aged between 0 and 12 months, and a second dose is administered to the patient aged between 12 and 24 months.

Abstract: The present invention relates to Neisseria ORF2086 proteins, crossreactive immunogenic proteins which can be isolated from nesserial strains or prepared recombinantly, including immunogenic portions thereof, biological equivalents thereof, antibodies that immunospecifically bind to the foregoing and nucleic acid sequences encoding each of the foregoing, as well as the use of same in immunogenic compositions that are effective against infection by Neisseria meningitidis serogroup B.

Abstract: The invention provides methods and compositions for preventing or ameliorating pulmonary infections with Pseudomonas aeruginosa.

Abstract: The present application relates to the field of human immunology, in particular, a chlamydia vaccine. The subunit vaccine composition may comprise isolated antigens from chlamydia bacteria, fusion proteins or fragments thereof, live or attenuated bacteria, or other bacterial components mixed in varied combination with a nanoemulsion, which provides a potent immune enhancer.

Abstract: The disclosed compositions and methods provide an approach for the rational development of a live attenuated virus to be used as a vaccine, vaccine seed strain, therapy, and/or research tool. Methods are disclosed to generate a virus that is phenotypically wild-type but genetically attenuated. The virus would ‘look’ like the pathogenic virus and, upon vaccination, the initial viral infection would be largely, if not fully, indistinguishable from that initiated by its pathogenic counterpart, leading to the most relevant and robust immune response. However, because the genome is attenuated, the viruses generated by the initial round of infection would be phenotypically attenuated. This approach can be applied to any virus that, upon the introduction of select mutations, can be propagated with an organism or system that utilizes an alternative genetic code.

Abstract: The disclosed compositions and methods provide an approach for the rational development of a nucleic acid vaccine. Methods are disclosed to deliver a viral genome, and/or a representative or derivative of such, that is attenuated but can, when co-delivered with unreplicable compensatory translational tools to a host cell, initially generate phenotypically wild-type, genetically attenuated viruses which infect subsequent cells and elicit a relevant and robust immune response. However, progeny of this initial generation, lacking the compensatory tools delivered to the initial host cells, are both phenotypically and genetically attenuated, thereby compromised in their ability to induce disease.

Abstract: Poxvirus vectors encoding a synthetic HIV envelope antigen and other HIV antigens, as well as compositions containing such poxvirus vectors and uses of such poxvirus vectors as vaccines to provide improved immunity against HIV, are provided. Also provided are vaccine combinations containing the disclosed poxvirus vectors, adenovirus vectors encoding one or more HIV antigens, and one or more isolated HIV antigenic polypeptides, and methods of using the vaccine combinations to provide improved immunity against HIV.